TAU IMMUNOTHERAPY FOR ALZHEIMER’S (Review Article)
DOI:
https://doi.org/10.52340/jecm.2022.02.15Abstract
Alzheimer's is a tormenting disease that progressively destroys a person's cognition. Researchers have toiled long and hard to find a cure or slow the course of this disease. Therapies have mainly targeted the two hallmarks of Alzheimer's pathophysiology: amyloid and tau protein. This paper sheds light on the new developments in the field of immunotherapy aimed against tau protein, particularly in comparison to the thus far futile efforts of targeting amyloid. Tau targeting immunotherapy is emerging as a promising therapeutic option.
Downloads
References
Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement 2016;12(4):459-509.
Bloom GS. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 2014;71(4):505-08.
Yu YJ, Watts RJ. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics 2013;10(3):459–72.
Panza, F, Frisardi V, Solfrizzi V, et al. Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies. Immunotherapy 2012;4(2):213–38.
Arbor SC, LaFontaine M, Cumbay M. Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores. Yale J Biol Med 2016;89(1):5-21.
Folch J, Ettcheto M, Petrov D, et al. Review of the advances in treatment for Alzheimer disease: Strategies for combating β-amyloid protein. Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteína β-amiloide. Neurologia (Engl Ed) 2018;33(1):47-58.
Darrow JJ, Kesselheim AS. A New Wave of Vaccines for Non-Communicable Diseases: What Are the Regulatory Challenges? Food Drug Law Journal 2015;70(2):243-i.
Congdon, EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nature reviews Neurology 2018;14(7):399–415.
Panza F, Lozupone M, Seripa D, Imbimbo BP. Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot? Ann Neurol 2019;85(3):303-15.
Lemere CA. Immunotherapy for Alzheimer’s disease: hoops and hurdles. Mol Neurodegeneration 2013;8:36.
Rosenmann H, Grigoriadis N, Karussis D, et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 2006;63(10):1459–67.
Lebouvier T, Pasquier F, Buée L. Update on tauopathies. Curr Opin Neurol 2017;30(6):589-98.
Patton BL, Miller SG, Kennedy MB. Identification of Functionally Significant Phosphorylation Sites on Neuronal Proteins and Preparation of Antibodies That Recognize Them. Methods in Neurosciences Neuropeptide Technology - Synthesis, Assay, Purification, and Processing 1991;158-76.
Weller J, Budson A. Current understanding of Alzheimer's disease diagnosis and treatment. F1000 Faculty Rev 2018;1161.
Novak P, Schmidt R, Kontsekova E, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol 2017;16(2):123-34.
Rygiel K. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies. Indian J Pharmacol 2016;48(6):629-36.
Castillo-Carranza DL, Sengupta U, Guerrero-Muñoz MJ, et al. Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 2014; 34:4260–72.
Viola KL, Klein WL. Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol 2015;129(2):183-206.
Buee L, Bussiere T, Buee-Scherrer V, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000;33(1):95–130.
Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther 2014;6(4):44.
Czerkowicz J, Chen W, Wang Q, et al. Pan-tau antibody Biib076 exhibits promising safety and biomarker profile in cynomolgus monkey toxicity study. Alzheimer’s Dementia 2017;13(7):1271.
Alam R, Driver D, Wu S, et al. Preclinical characterization of an antibody [LY3303560] targeting aggregated tau. Alzheimer’s Dementia 2017;13(7):592–93.
Folch J, Ettcheto M, Petrov D, et al. Review of the advances in treatment for Alzheimer disease: Strategies for combating β-amyloid protein. Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteína β-amiloide. Neurologia (Engl Ed) 2018;33(1):47-58.
Kontsekova E, Zilka N, Kovacech B, Skrabana R, Novak M. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease. Alz Res Therapy 2014;6(4):45.
Galpern WR, Mercken M, Van Kolen K., et al. P1‐052: A single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-phospho-TAU antibody JNJ‐63733657 in healthy subjects. Alzheimer's & Dementia. 2019; 15:252-53.
Novak P, Schmidt R, Kontsekova E et al. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease. Alz Res Therapy 2018;10(1):108.
Chong FP, Ng KY, Koh RY, Chye SM. Tau Proteins and Tauopathies in Alzheimer's Disease. Cell Mol Neurobiol 2018;38(5):965-80.
Albert M, Mairet-Coello G, Danis C, et al. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain 2019;142(6):1736-50.
Downloads
Published
How to Cite
Issue
Section
